|
1
|
Rowley JD: Letter: A new consistent
chromosomal abnormality in chronic myelogenous leukaemia identified
by quinacrine fluorescence and Giemsa staining. Nature.
243:290–293. 1973. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
de Klein A, van Kessel AG, Grosveld G,
Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N,
Groffen J and Stephenson JR: A cellular oncogene is translocated to
the Philadelphia chromosome in chronic myelocytic leukaemia.
Nature. 300:765–767. 1982. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bernt KM and Hunger SP: Current concepts
in pediatric Philadelphia chromosome-positive acute lymphoblastic
leukemia. Front Oncol. 4:542014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barnes DJ and Melo JV: Cytogenetic and
molecular genetic aspects of chronic myeloid leukaemia. Acta
Haematol. 108:180–202. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jinawath N, Norris-Kirby A, Smith BD,
Gocke CD, Batista DA, Griffin CA and Murphy KM: A rare e14a3 (b3a3)
BCR-ABL fusion transcript in chronic myeloid leukemia: Diagnostic
challenges in clinical laboratory practice. J Mol Diagn.
11:359–363. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pallisgaard N, Hokland P, Riishøj DC,
Pedersen B and Jørgensen P: Multiplex reverse
transcription-polymerase chain reaction for simultaneous screening
of 29 translocations and chromosomal aberrations in acute leukemia.
Blood. 92:574–588. 1998.PubMed/NCBI
|
|
7
|
Bernards A, Rubin CM, Westbrook CA,
Paskind M and Baltimore D: The first intron in the human c-abl gene
is at least 200 kilobases long and is a target for translocations
in chronic myelogenous leukemia. Mol Cell Biol. 7:3231–3236. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nieborowska-Skorska M, Wasik MA, Slupianek
A, Salomoni P, Kitamura T, Calabretta B and Skorski T: Signal
transducer and activator of transcription (STAT)5 activation by
BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains
of BCR/ABL and is required for leukemogenesis. J Exp Med.
189:1229–1242. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Skorski T, Nieborowska-Skorska M,
Wlodarski P, Wasik M, Trotta R, Kanakaraj P, Salomoni P, Antonyak
M, Martinez R, Majewski M, et al: The SH3 domain contributes to
BCR/ABL-dependent leukemogenesis in vivo: Role in adhesion,
invasion, and homing. Blood. 91:406–418. 1998.PubMed/NCBI
|
|
10
|
Iwata S, Mizutani S, Nakazawa S and Yata
J: Heterogeneity of the breakpoint in the ABL gene in cases with
BCR/ABL transcript lacking ABL exon a2. Leukemia. 8:1696–1702.
1994.PubMed/NCBI
|
|
11
|
Polák J, Zemanová Z, Michalová K, Klamová
H, Cermák J and Haskovec C: A new case of chronic myeloid leukemia
(CML) in myeloid blast crisis with an atypical (b3/a3) junction of
the BCR/ABL gene. Leukemia. 12:2501998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Amabile M, Martinelli G, Terragna C,
Montefusco V, Tabilio A and Tura S: An atypical (b3/a3) junction of
the bcr/abl gene lacking abl exon a2 in a patient with chronic
myeloid leukemia. Haematologica. 84:573–575. 1999.PubMed/NCBI
|
|
13
|
Paz-Y-Miño C, Arévalo M and Leone PE:
B3/A3 rearrangement in a patient with chronic myeloid leukemia.
Leuk Lymphoma. 44:375–376. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vaniawala S, Acharya A, Parekh H and
Mukhopadhyaya PN: Rare e14a3 (b3a3) BCR-ABL fusion in chronic
myeloid leukemia in India: The threats and challenges in monitoring
minimal residual disease (MRD). Anal Cell Pathol (Amst). 36:85–92.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xiaomin G, Zhang Y, Pan J, Qiu H, Cen J,
Xue Y, Chen S, Shen H, Yao L, Zhang J, et al: Chronic myeloid
leukemia with e14a3 BCR-ABL transcript: Analysis of characteristics
and prognostic significance. Leuk Lymphoma. 56:3343–3347. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tiribelli M, Tonso A, Ferrro D, Parzilae
A, Cambrin GR, Scaravaglio P, Cilloni D, Gottardi E and Saglio G:
Lack of SH3 domain does not imply a more severe clinical course in
Ph+ chronic myeloid leukemia patients. Blood. 95:4019–4020.
2000.PubMed/NCBI
|
|
17
|
Kreuzer KA, Lass U, Bohn A, Landt O and
Schmidt CA: LightCycler technology for the quantitation of bcr/abl
fusion transcripts. Cancer Res. 59:3171–3144. 1999.PubMed/NCBI
|
|
18
|
Hanfstein B, Lauseker M, Hehlmann R,
Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S,
Haferlach C, et al: Distinct characteristics of e13a2 versus e14a2
BCR-ABL1 driven chronic myeloid leukemia under first-line therapy
with imatinib. Haematologica. 99:1441–1457. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jain P, Kantarjian H, Patel KP, Gonzalez
GN, Luthra R, Shamanna Kanagal R, Sasaki K, Jabbour E, Romo CG,
Kadia TM, et al: Impact of BCR-ABL transcript type on response and
survival in patients with chronic-phase chronic myeloid leukemia
treated with tyrosine kinase inhibitors. Blood. 127:1269–1275.
2016. View Article : Google Scholar : PubMed/NCBI
|
